| Literature DB >> 21873545 |
Madhu S Kumar1, Anupama Narla, Atsushi Nonami, Ann Mullally, Nadya Dimitrova, Brian Ball, J Randall McAuley, Luke Poveromo, Jeffrey L Kutok, Naomi Galili, Azra Raza, Eyal Attar, D Gary Gilliland, Tyler Jacks, Benjamin L Ebert.
Abstract
Large chromosomal deletions are among the most common molecular abnormalities in cancer, yet the identification of relevant genes has proven difficult. The 5q- syndrome, a subtype of myelodysplastic syndrome (MDS), is a chromosomal deletion syndrome characterized by anemia and thrombocytosis. Although we have previously shown that hemizygous loss of RPS14 recapitulates the failed erythroid differentiation seen in 5q- syndrome, it does not affect thrombocytosis. Here we show that a microRNA located in the common deletion region of 5q- syndrome, miR-145, affects megakaryocyte and erythroid differentiation. We find that miR-145 functions through repression of Fli-1, a megakaryocyte and erythroid regulatory transcription factor. Patients with del(5q) MDS have decreased expression of miR-145 and increased expression of Fli-1. Overexpression of miR-145 or inhibition of Fli-1 decreases the production of megakaryocytic cells relative to erythroid cells, whereas inhibition of miR-145 or overexpression of Fli-1 has a reciprocal effect. Moreover, combined loss of miR-145 and RPS14 cooperates to alter erythroid-megakaryocytic differentiation in a manner similar to the 5q- syndrome. Taken together, these findings demonstrate that coordinate deletion of a miRNA and a protein-coding gene contributes to the phenotype of a human malignancy, the 5q- syndrome.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21873545 PMCID: PMC3208282 DOI: 10.1182/blood-2010-12-324715
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113